Search Results for "Tingkatan Satu Sejarah Nota"

15:55 EDT 23rd August 2014 | BioPortfolio

Matching Channels

None

Matching News

Pleo Homeopathic Drug Products by Terra-Medica: Recall - Potential for Undeclared Penicillin

Audience: Consumer Includes Pleo-FORT, Pleo-QUENT, Pleo-NOT, Pleo-STOLO, Pleo-NOTA-QUENT, and Pleo-EX [Posted 03/20/2014] ISSUE: Terra-Medica, Inc. is voluntarily recalling 56 lots of Pleo-FORT, Ple...

Nota Lepidopterologica goes advanced open access with Pensoft Publishers

(Pensoft Publishers) The Societas Europaea Lepidopterologica has joined forces with Pensoft Publishers to bring the Society's journal Nota Lepidopterologica on the way to open access and innovation. T...

Invoiceware International Selected by Sigma-Aldrich To Simplify Compliance with Brazil's Nota Fiscal E-Invoicing Legislation

ATLANTA, July 1, 2014 /PRNewswire-iReach/ -- Invoiceware International, the largest Latin America Business Network, has been selected by Sigma-Aldrich, a leading Life Science and High Technology compa...

Trust the "trust hormone"? Oxytocin can increase deceit

Oxytocin has perhaps the best reputation of any molecule on the planet. In a culture of chemophobia where any compound is fair game for attack, oxytocin has been heralded as "The Source of Love and Pr...

ValiRx gets MHRA approval for phase I/II cancer trial

ValiRx (LON:VAL) has received the go-ahead from the UK licensing authority (MHRA) for a Phase I/II trial for its lead product in prostate cancer and other advanced solid tumours.  The trial will...

ValiRx lead treatment moves to human stage cancer trial

ValiRx (LON:VAL) applied to the UK Medicines Agency for permission to carry out a phase I/II trial on VAL201, its lead cancer treatment.   The dose escalation study will assess the safety and tol...

|UPDATE - ValiRx gets MHRA approval for phase I/II cancer trial

-- adds broker target-- Shares is ValiRx (LON:VAL) shot higher as it confirmed Uk regulatory approval for a Phase I/II trial for its lead product that treats prostate cancer and other advanced solid t...

ValiRx sets up joint venture to advance lung cancer drug

ValiRx (LON:VAL) has set up a joint venture firm with Tangent Reprofiling Ltd to advance a treatment for lung cancer, for which the market is valued at around US$5 billion. ValiSeek has purchased the...

Matching PubMed Articles

PET imaging of prostate tumors with (18) F-Al-NOTA-MATBBN.

Overexpression of the gastrin-releasing peptide receptor (GRPR) in prostate cancer provides a promising target for detection the disease. MATBBN is a new bombesin analog originating from the GRPR anta...

Comparison of 18F-AIF-NOTA-PRGD2 and 18F-FDG Uptake in Lymph Node Metastasis of Differentiated Thyroid Cancer.

A widespread application of integrin αvβ3 imaging has been emerging in both pre-clinical and clinical studies. But few studies reported its value as compared with 18F-FDG PET, especially for differe...

Pilot Study of a Novel (18)F-labeled FSHR Probe for Tumor Imaging.

Follicle-stimulating hormone receptor (FSHR) is overexpressed in primary and metastatic tumor. Molecular imaging of FSHR is beneficial for prognosis and therapy of cancer. FSHβ(33-53) (YTRDLVYKDPARPK...

The Effect of Mini-PEG-Based Spacer Length on Binding and Pharmacokinetic Properties of a 68Ga-Labeled NOTA-Conjugated Antagonistic Analog of Bombesin.

The overexpression of gastrin-releasing peptide receptor (GRPR) in cancer can be used for peptide-receptor mediated radionuclide imaging and therapy. We have previously shown that an antagonist analog...

(68)Ga-NOTA-CHSg and (99m)Tc-CHSg Labeled Microspheres for Lung Perfusion and Liver Radiomicrospheres Therapy Planning.

Fast biodegradable (12 h < half-life < 48 h) radioactive labeled microspheres are needed for PET and SPECT lung perfusion and radiomicrosphere therapy planning. An emulsion method was used to crea...

Search Whole site using Google

Loading
Search BioPortfolio:
Advertisement
Advertisement
Advertisement Advertisement